Drug Development - Targeting HER2 beyond Trastuzumab

被引：0
|
作者：
Spector, N. L. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-PL2-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PL2-1
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
  • [42] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [43] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [44] Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer
    Watanabe, Satomi
    Yonesaka, Kimio
    Tanizaki, Junko
    Nonagase, Yoshikane
    Takegawa, Naoki
    Haratani, Koji
    Kawakami, Hisato
    Hayashi, Hidetoshi
    Takeda, Masayuki
    Tsurutani, Junji
    Nakagawa, Kazuhiko
    CANCER MEDICINE, 2019, 8 (03): : 1258 - 1268
  • [45] Combined targeting of HER2 and HER3 inhibits tumor growth in both trastuzumab-sensitive and trastuzumab-resistant breast cancer models.
    Steiner, Philipp
    Wetzel, Leslie
    Schifferli, Kevin
    Rothstein, Raymond
    Tammali, Ravinder
    Rebelatto, Marlon
    Xiao, Zhan
    Pierce, Andrew
    Hollingsworth, Robert
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [46] Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
    Ishimine, Yu
    Goto, Akira
    Watanabe, Yoshito
    Yajima, Hidetaka
    Nakagaki, Suguru
    Yabana, Takashi
    Adachi, Takeya
    Kondo, Yoshihiro
    Kasai, Kiyoshi
    CASE REPORTS IN GASTROINTESTINAL MEDICINE, 2015, 2015
  • [47] Evaluating Trastuzumab in the treatment of HER2 positive breast cancer
    Jaques, Ryan
    Xu, Sam
    Matsakas, Antonios
    HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (10) : 1059 - 1075
  • [48] intrathecal trastuzumab in HER2 positive tumors with meningeal involvement
    Hofer, S.
    Mengele, K.
    Stemmler, H. J.
    Schmitt, M.
    Pestalozzi, B.
    ONKOLOGIE, 2012, 35 : 244 - 244
  • [49] Extravascular distribution of trastuzumab in Her2/neu overexpressing xenografts
    Baker, Jennifer H. E.
    Lindquist, Kirstin E.
    Huxham, Lynsey A.
    Kyle, Alastair H.
    Sy, Jonathan T.
    Minchinton, Andrew I.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3473S - 3473S
  • [50] Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer
    Hayashi, Tetsutaro
    Seiler, Roland
    Oo, Htoo Zarni
    Jaeger, Wolfgang
    Moskalev, Igor
    Awrey, Shannon
    Dejima, Takashi
    Todenhoefer, Tilman
    Li, Na
    Fazli, Ladan
    Matsubara, Akio
    Black, Peter C.
    JOURNAL OF UROLOGY, 2015, 194 (04): : 1120 - 1131
12345